Pact Pharma Stock

pactpharma.comHealthcareFounded: 2017Funding to Date: $354.6MM

PACT Pharma clinical stage biotechnology company developing personalized adoptive T cell therapies for the eradication of solid tumors.

Register for Details

For more details on financing and valuation for Pact Pharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Pact Pharma.

Register Today

Team

Management Team

Alex Franzusoff Ph.D
Chief Scientific Officer
Antoni Ribas Ph.D
Scientific Co-Founder & Board Member
Timothy Moore
Chief Technical Officer & President
Juan Jaen Ph.D
Co-Founder & Board Member
James Heath Ph.D
Scientific Co-Founder & Board Member
David Baltimore Ph.D
Scientific Co-Founder & Chairman of Scientific Advisory Board
Terry Rosen Ph.D
Co-Founder & Board Member
Blake Byers Ph.D
Interim President & Board Member

Board Members

Antoni Ribas Ph.D
Juan Jaen Ph.D
Terry Rosen Ph.D
David Baltimore Ph.D
James Heath Ph.D
Blake Byers Ph.D
KT Moortgat Ph.D
AbbVie Ventures

Other companies like Pact Pharma in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing
South San Francisco-based PACT Pharma, a provider of personalized cell therapy for solid tumors, has appointed Tim Moore as president and chief technical officer. Previously, Moore worked at Kite where he was executive vice president of technical operations. PACT Pharma's backers included GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus, Pontifax, Wu Capital, AbbVie Ventures and Taiho Ventures.